SEC Comment Letter for REPLIGEN CORP (RGEN) (CIK 0000730272) (RGEN) — Sep 10, 2025

REPLIGEN CORP (RGEN) (CIK 0000730272)
Date: Sept. 10, 2025 · CIK: 0000730272 · Accession: 0000000000-25-009806

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-14656

Date

September 10, 2025

Author

Finance

Form

UPLOAD

Company

REPLIGEN CORP (RGEN) (CIK 0000730272)

Letter

Re: Repligen Corporation Form 10-K for Fiscal Year Ended December 31, 2024 File No. 000-14656 Dear Jason K. Garland:

September 10, 2025

Jason K. Garland Chief Financial Officer Repligen Corporation 41 Seyon Street Building 1, Suite 100 Waltham, MA 02453

We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,
Division of Corporation
Finance
Office of Life Sciences

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 September 10, 2025

Jason K. Garland
Chief Financial Officer
Repligen Corporation
41 Seyon Street
Building 1, Suite 100
Waltham, MA 02453

 Re: Repligen Corporation
 Form 10-K for Fiscal Year Ended December 31, 2024
 File No. 000-14656
Dear Jason K. Garland:

 We have completed our review of your filings. We remind you that the
company and
its management are responsible for the accuracy and adequacy of their
disclosures,
notwithstanding any review, comments, action or absence of action by the staff.

 Sincerely,

 Division of Corporation
Finance
 Office of Life Sciences
</TEXT>
</DOCUMENT>

SecProbe.io